GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: August 25, 2002, 06:13:45 ; Search time 200.96 Seconds
(without alignments)
9158.700 Million cell updates/sec

Title: US-09-811-118-2
Perfect score: 1072
Sequence: 1 GACGCCGCCACCTCCGGAAC.....TTGCATCCAACATGAATTTC 1072

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 1736436 seqs, 858457221 residues

Word size : 0

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	1072	100.0	1072	22	AAH46980	Human glutathione
	2	921	85.9	1100	22	AAI58027	Human polynucleoti
	3	921	85.9	1205	22	AAI59813	Human polynucleoti
	4	921	85.9	1321	21	AAC98225	Human colon cancer
	5	921	85.9	1511	22	AAH72778	Human cervical can
	6	919	85.7	1228	22	AAH14527	Human cDNA sequenc
	7	916	85.4	1227	21	AAZ65013	Membrane-bound pro
	8	916	85.4	1227	22	AAS46137	Human DNA encoding
	9	916	85.4	1227	22	AAF44159	Human PRO828 (UNQ4
	10	882	82.3	1315	22	AAF81788	Human secreted pro
	11	632	59.0	872	22	AAH06810	Human cDNA clone (
c	12	361	33.7	751	22	AAH71016	Human cervical can
c	13	356	33.2	468	22	AAH72087	Human cervical can
c	14	343	32.0	528	22	AAH11842	Human cDNA clone (
	15	50	4.7	50	21	AAZ65182	Probe specific for
	16	42	3.9	51	22	AAF44339	Human PRO828 hybri
	17	24	2.2	24	21	AAZ65180	Primer amplifying
c	18	24	2.2	24	21	AAZ65181	Primer amplifying
	19	24	2.2	24	22	AAF44337	Human PRO828 forwa
c	20	24	2.2	24	22	AAF44338	Human PRO828 rever
c	21	22	2.1	1380	23	ABL21703	Drosophila melanog
c	22	22	2.1	4181	23	ABL21702	Drosophila melanog
	23	21	2.0	828	9	AAN80912	Sequence encoding
c	24	21	2.0	30967	17	AAT32454	Calpain large subu
	25	21	2.0	49998	20	AAX23518	Human kidney amino
	26	20	1.9	1557	21	AAC99034	Human pancreatic c
	27	20	1.9	1557	22	AAS00830	Human cDNA clone H
	28	19	1.8	293	16	AAT24182	Human gene signatu
c	29	19	1.8	519	22	AAH11799	Human cDNA clone (
c	30	19	1.8	739	22	AAS28421	Genomic sequence #
c	31	19	1.8	739	22	AAS28422	Genomic sequence #
	32	19	1.8	2000	16	AAQ87925	Erythroid p55 geno
	33	19	1.8	2030	21	AAC98843	Human pancreatic c
	34	19	1.8	2372	22	AAD04887	Human colon tumour
	35	19	1.8	2483	21	AAA39511	Human tumour prote
c	36	19	1.8	2790	19	AAV28916	Human semaphorin Y
	37	19	1.8	2951	22	AAH16325	Human cDNA sequenc
c	38	19	1.8	3432	19	AAV28915	Human semaphorin Y
c	39	19	1.8	3575	22	AAH57402	Human skeletal mus
c	40	19	1.8	3597	22	AAI57881	Human polynucleoti
c	41	19	1.8	3603	22	AAI59667	Human polynucleoti
c	42	19	1.8	3870	22	AAH52059	Mycobacterium tube
c	43	19	1.8	5379	24	ABL33677	Human immune syste
c	44	19	1.8	5379	24	ABL34577	Human metastasis a
	45	19	1.8	4403765	22	AAI99683	Mycobacterium tube

ALIGNMENTS

RESULT 1
AAH46980
ID AAH46980 standard; cDNA; 1072 BP.
XX
AC AAH46980;
XX
DT 29-OCT-2001 (first entry)
XX
DE Human glutathione peroxidase (GPx6) encoding cDNA.
XX
KW Glutathione peroxidase; GPx6; anti-human immunodeficiency virus; HIV;
KW antiinflammatory; antiallergic; antiasthmatic; antiatherosclerotic;
KW antianemic; antithyroid; immunosuppressive; antidiabetic; nephrotropic;
KW antigout; neuroprotective; osteopathic; antirheumatic; antiarthritic;
KW tranquilizer; vulnerary; antiarteriosclerotic; hepatotropic; human;
KW antipsoriatic; cytostatic; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 26..589
FT /*tag= a
FT /product= "GPx6"
XX
PN US6231853-B1.
XX
PD 15-MAY-2001.
XX
PF 01-JUN-1998; 98US-0088549.
XX
PR 01-JUN-1998; 98US-0088549.
XX

PA (INCY-) INCYTE PHARM INC.
XX
PI Hillman JL, Corley NC, Patterson C;
XX
DR WPI; 2001-335067/35.
DR P-PSDB; AAB85575.
XX
PT New substantially purified human glutathione peroxidase polypeptide,
PT useful for diagnosing, treating or preventing reproductive disorders,
PT immune disorders and cell proliferative or developmental disorders -
XX
PS Example 1; Fig 1A-C; 26pp; English.
XX
CC This cDNA encodes a human glutathione peroxidase (GPx6) polypeptide. The
CC GPx6 polypeptide is useful for diagnosing, treating or preventing
CC disorders associated with expression of GPx6, where the disorders are
CC selected from reproductive disorders, immune disorders such as acquired
CC immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory
CC distress syndrome, allergies, asthma, atherosclerosis, anemia, autoimmune
CC thyroiditis, bronchitis, diabetes mellitus, glomerulonephritis,
CC Goodpasture's syndrome, gout, multiple sclerosis, myasthenia gravis,
CC osteoporosis, rheumatoid arthritis, cancer, infections and trauma, and
CC cell proliferative or development disorders such as arteriosclerosis,
CC cirrhosis, psoriasis, cancer, Cushing's syndrome, and Syndenham's chorea.
CC GPx6 is also useful to produce antibodies, and to screen libraries of
CC pharmaceutical agents to identify those which specifically binds GPx6.
XX
SQ Sequence 1072 BP; 275 A; 294 C; 270 G; 233 T; 0 other;

Query Match 100.0%; Score 1072; DB 22; Length 1072;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1072; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 60

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 120

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 180

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 240

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 agacctgggccccccaccacttcaacgtgctcgccttccccctgcaaccagtttggccaaca 300

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 ggagcctgacagcaacaaggagattgagagctttgcctgccgcacctacagtgtctcatt 360

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 420

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 480

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagactccagat 540

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 600

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 660

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 720

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 780

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 840

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 900

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 960

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     961 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatat 1020

Qy    1021 AAACCAAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1021 aaaccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1072
```

RESULT 2
AAI58027
ID AAI58027 standard; cDNA; 1100 BP.
XX
AC AAI58027;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 230.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

```
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM38871.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 230; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1100 BP; 288 A; 305 C; 277 G; 230 T; 0 other;


  Query Match             85.9%;  Score 921;  DB 22;  Length 1100;
  Best Local Similarity   99.8%;  Pred. No. 0;
  Matches 1021;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 82

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      83 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 142

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     143 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 202

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     203 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 262

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     263 agacctgggccccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 322

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
           |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     323 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 382

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     383 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 442

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     443 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 502

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     503 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 562

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     563 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 622

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     623 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 682

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     683 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 742

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     743 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 802

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     803 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 862

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     863 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 922

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     923 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 982

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     983 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatat 1042

Qy    1021 AAA 1023
           |||
Db    1043 aaa 1045


RESULT   3
AAI59813
ID   AAI59813 standard; cDNA; 1205 BP.
XX
AC   AAI59813;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 3802.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
```

```
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM40657.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 3802; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1205 BP; 324 A; 321 C; 289 G; 271 T; 0 other;

  Query Match             85.9%;  Score 921;  DB 22;  Length 1205;
  Best Local Similarity   99.8%;  Pred. No. 0;
  Matches 1021;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 61

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      62 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 121

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     122 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 181

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     182 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 241

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     242 agacctgggccccaccacttcaacgtgctcgccttccctgcaaccagtttggccaaca 301

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
           |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     302 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 361

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     362 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 421

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     422 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 481

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     482 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 541

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     542 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 601

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     602 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 661

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     662 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 721

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     722 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 781

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     782 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 841

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     842 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 901

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     902 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 961

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     962 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatat 1021

Qy    1021 AAA 1023
           |||
Db    1022 aaa 1024


RESULT   4
AAC98225
ID   AAC98225 standard; cDNA; 1321 BP.
XX
AC   AAC98225;
XX
DT   09-MAR-2001  (first entry)
XX
DE   Human colon cancer antigen nucleotide sequence SEQ ID NO:235.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW   immunomodulatory; muscular; gynaecological; gastrointestinal;
KW   nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW   neural disorder; immune system disorder; muscular disorder;
KW   reproductive disorder; gastrointestinal disorder; renal disorder;
KW   infectious disease; cardiovascular disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200055351-A1.
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US05883.
XX
PR   12-MAR-1999;   99US-0124270.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM;
XX
DR   WPI; 2000-587534/55.
DR   P-PSDB; AAB53468.
XX
PT   Colon cancer associated gene sequences, referred to as colon cancer
PT   antigens, useful for the treatment, prevention, and diagnosis of colon
PT   disorders such as colon cancer -
XX
PS   Claim 1; Page 656-657; 2104pp; English.
XX
```

```
CC   AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC   called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC   human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC   neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC   vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC   can be used in gene therapy. The colon cancer antigen polynucleotides,
CC   proteins and antibodies to the proteins are useful for the prevention,
CC   treatment and diagnosis of colon disorders, such as colon cancer. The
CC   polynucleotides may be used in diagnostics and research, such as for
CC   chromosome identification, and as hybridisation probes. The proteins
CC   may also be used to prevent diseases such as neural disorders, immune
CC   system disorders, muscular disorders, reproductive disorders,
CC   gastrointestinal disorders, wounds, renal disorders, infectious
CC   diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC   AAB54007 represent sequences used in the exemplification of the present
CC   invention.
XX
SQ   Sequence 1321 BP; 420 A; 326 C; 296 G; 276 T; 3 other;


  Query Match             85.9%;  Score 921;  DB 21;  Length 1321;
  Best Local Similarity   99.8%;  Pred. No. 0;
  Matches 1021;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       5 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 64

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      65 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 124

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     125 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 184

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     185 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 244

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     245 agacctgggccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 304

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
           |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     305 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 364

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     365 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 424

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     425 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 484

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     485 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 544

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     545 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 604

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     605 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 664

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     665 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 724

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     725 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 784

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     785 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 844

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     845 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 904

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     905 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 964

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     965 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatat 1024

Qy    1021 AAA 1023
           |||
Db    1025 aaa 1027


RESULT   5
AAH72778
ID   AAH72778 standard; cDNA; 1511 BP.
XX
AC   AAH72778;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 4052.
XX
KW   Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681.
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600.
PR   21-JUL-2000; 2000US-0220114.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Deeds J,  Berger A,  Zhao X;
XX
DR   WPI; 2001-375006/39.
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 845-847; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 1511 BP; 392 A; 421 C; 378 G; 314 T; 6 other;
```

```
  Query Match             85.9%;  Score 921;  DB 22;  Length 1511;
  Best Local Similarity   99.8%;  Pred. No. 0;
  Matches 1021;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     276 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 335

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     336 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 395

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     396 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 455

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     456 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 515

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     516 agacctgggccccaccacttcaacgtgctcgccttccctgcaaccagtttggccaaca 575

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     576 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 635

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     636 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 695

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     696 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 755

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     756 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 815

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     816 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 875

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     876 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 935

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     936 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 995

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     996 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 1055

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1056 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 1115

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1116 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 1175

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1176 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 1235

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1236 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatat 1295
```

```
Qy   1021 AAA 1023
          |||
Db   1296 aaa 1298
```

RESULT 6
AAH14527
ID AAH14527 standard; cDNA; 1228 BP.
XX
AC AAH14527;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human cDNA sequence SEQ ID NO:12070.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
PS Claim 8; SEQ ID 12070; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 1228 BP; 326 A; 330 C; 290 G; 282 T; 0 other;

```
  Query Match             85.7%;  Score 919;  DB 22;  Length 1228;
  Best Local Similarity   99.7%;  Pred. No. 0;
```

```
  Matches 1069;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      15 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 74

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      75 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 134

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     135 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 194

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     195 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 254

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db     255 agacctgggccccaccactttaacgtgctcgccttcccctgcaaccagtttggccaaca 314

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     315 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 374

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     375 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 434

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     435 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 494

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     495 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 554

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     555 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 614

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     615 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 674

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     675 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 734

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     735 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 794

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     795 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 854

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     855 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 914

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     915 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 974

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     975 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatat 1034

Qy    1021 AAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1035 aaaccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1086
```

```
RESULT   7
AAZ65013
ID   AAZ65013 standard; cDNA; 1227 BP.
XX
AC   AAZ65013;
XX
DT   05-APR-2000  (first entry)
XX
DE   Membrane-bound protein PRO828 encoding cDNA.
XX
KW   Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW   pharmaceutical; receptor immunoadhesin; gene mapping; ss.
XX
OS   Homo sapiens.
XX
PN   WO9963088-A2.
XX
PD   09-DEC-1999.
XX
PF   02-JUN-1999;   99WO-US12252.
XX
PR   02-JUN-1998;   98US-0087607.
PR   02-JUN-1998;   98US-0087609.
PR   02-JUN-1998;   98US-0087759.
PR   03-JUN-1998;   98US-0087827.
PR   04-JUN-1998;   98US-0088021.
PR   04-JUN-1998;   98US-0088025.
PR   04-JUN-1998;   98US-0088028.
PR   04-JUN-1998;   98US-0088029.
PR   04-JUN-1998;   98US-0088030.
PR   04-JUN-1998;   98US-0088033.
PR   04-JUN-1998;   98US-0088326.
PR   05-JUN-1998;   98US-0088167.
PR   05-JUN-1998;   98US-0088202.
PR   05-JUN-1998;   98US-0088212.
PR   05-JUN-1998;   98US-0088217.
PR   09-JUN-1998;   98US-0088655.
PR   10-JUN-1998;   98US-0088722.
PR   10-JUN-1998;   98US-0088730.
PR   10-JUN-1998;   98US-0088734.
PR   10-JUN-1998;   98US-0088738.
PR   10-JUN-1998;   98US-0088740.
PR   10-JUN-1998;   98US-0088741.
PR   10-JUN-1998;   98US-0088742.
PR   10-JUN-1998;   98US-0088810.
PR   10-JUN-1998;   98US-0088811.
PR   10-JUN-1998;   98US-0088824.
PR   10-JUN-1998;   98US-0088825.
PR   10-JUN-1998;   98US-0088826.
PR   11-JUN-1998;   98US-0088858.
PR   11-JUN-1998;   98US-0088861.
PR   11-JUN-1998;   98US-0088863.
PR   11-JUN-1998;   98US-0088876.
PR   12-JUN-1998;   98US-0089090.
PR   12-JUN-1998;   98US-0089105.
PR   16-JUN-1998;   98US-0089440.
PR   16-JUN-1998;   98US-0089512.
PR   16-JUN-1998;   98US-0089514.
PR   17-JUN-1998;   98US-0089532.
PR   17-JUN-1998;   98US-0089538.
PR   17-JUN-1998;   98US-0089598.
PR   17-JUN-1998;   98US-0089599.
PR   17-JUN-1998;   98US-0089600.
PR   17-JUN-1998;   98US-0089653.
PR   18-JUN-1998;   98US-0089801.
PR   18-JUN-1998;   98US-0089907.
PR   18-JUN-1998;   98US-0089908.
PR   19-JUN-1998;   98US-0089947.
PR   19-JUN-1998;   98US-0089948.
PR   19-JUN-1998;   98US-0089952.
PR   22-JUN-1998;   98US-0090246.
```

PR 22-JUN-1998; 98US-0090252.
PR 22-JUN-1998; 98US-0090254.
PR 23-JUN-1998; 98US-0090349.
PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091626.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 02-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091978.
PR 07-JUL-1998; 98US-0091982.
PR 09-JUL-1998; 98US-0092182.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.
PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
DR WPI; 2000-072883/06.
DR P-PSDB; AAY66677.
XX
PT Membrane-bound proteins and related nucleotide sequences -
XX
PS Claim 2; Fig 119; 822pp; English.
XX
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX
SQ Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other;

Query Match 85.4%; Score 916; DB 21; Length 1227;
Best Local Similarity 99.7%; Pred. No. 0;
Matches 1066; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       4 GCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCTCCT 63
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      12 gccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgctcct 71

Qy      64 GTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAACAT 123
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      72 gtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaacat 131

Qy     124 CCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAATGT 183
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     132 ccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaatgt 191

Qy     184 GGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCGAGA 243
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     192 ggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcgaga 251

Qy     244 CCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACAGGA 303
          |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db     252 cctgggcccccaccactttaacgtgctcgccttccccctgcaaccagtttggccaacagga 311

Qy     304 GCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATTCCC 363
          |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     312 gcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcattccc 371

Qy     364 CATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCTGGC 423
```

```
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     372 catgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacctggc 431

Qy     424 CCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGATGG 483
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     432 ccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccagatgg 491

Qy     484 AAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGATCAC 543
           |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||
Db     492 aaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagatcac 551

Qy     544 AGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCTCCT 603
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     552 agcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtctcct 611

Qy     604 CCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGGTGC 663
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     612 cctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatggtgc 671

Qy     664 TTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCATCAT 723
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     672 ttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccatcat 731

Qy     724 TCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAA 783
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     732 tcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaataggaa 791

Qy     784 CTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAA 843
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     792 ctcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgccaa 851

Qy     844 CAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTA 903
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     852 caaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttctgta 911

Qy     904 AACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGA 963
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     912 aactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctgtga 971

Qy     964 AAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAA 1023
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     972 aagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatataaa 1031

Qy    1024 CCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1032 ccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1080


RESULT   8
AAS46137
ID   AAS46137 standard; cDNA; 1227 BP.
XX
AC   AAS46137;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human DNA encoding PRO polypeptide sequence #213.
XX
KW   PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep; ss;
KW   dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW   blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW   adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder;
KW   PCR primer.
XX
OS   Homo sapiens.
XX
PN   WO200168848-A2.
XX
PD   20-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US06520.
XX
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   03-MAR-2000; 2000US-187202P.
PR   06-MAR-2000; 2000US-186968P.
PR   14-MAR-2000; 2000US-189320P.
PR   14-MAR-2000; 2000US-189328P.
PR   15-MAR-2000; 2000WO-US06884.
PR   21-MAR-2000; 2000US-190828P.
PR   21-MAR-2000; 2000US-191007P.
PR   21-MAR-2000; 2000US-191048P.
PR   21-MAR-2000; 2000US-191314P.
PR   28-MAR-2000; 2000US-192655P.
PR   29-MAR-2000; 2000US-193032P.
PR   29-MAR-2000; 2000US-193053P.
PR   30-MAR-2000; 2000WO-US08439.
PR   04-APR-2000; 2000US-194449P.
PR   04-APR-2000; 2000US-194647P.
PR   11-APR-2000; 2000US-195975P.
PR   11-APR-2000; 2000US-196000P.
PR   11-APR-2000; 2000US-196187P.
PR   11-APR-2000; 2000US-196690P.
PR   11-APR-2000; 2000US-196820P.
PR   18-APR-2000; 2000US-198121P.
PR   18-APR-2000; 2000US-198585P.
PR   25-APR-2000; 2000US-199397P.
PR   25-APR-2000; 2000US-199550P.
PR   25-APR-2000; 2000US-199654P.
PR   03-MAY-2000; 2000US-201516P.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   05-JUN-2000; 2000US-209832P.
PR   28-JUL-2000; 2000WO-US20710.
PR   22-AUG-2000; 2000US-0644848.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000WO-US34956.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Chen J,  Desnoyers L,  Goddard A,  Godowski PJ,  Gurney AL;
PI   Pan J,  Smith V,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-602746/68.
DR   P-PSDB; AAU29236.
XX
PT   Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT   presence of tumours, such as prostate and breast tumours, in mammals and
PT   to screen for modulators of the compounds -
XX
PS   Claim 2; Fig 425; 774pp; English.
XX
CC   Sequences AAS45925-AAS46231 represent DNA molecules encoding and PCR
CC   primers for PRO polypeptides of the invention. The sequences of the
CC   invention can be used to detect the presence of a tumour in a mammal by
CC   comparing the level of expression of a PRO polypeptide in a test sample
CC   of cells from the animal and a control sample of normal cells, whereby a
CC   higher level of expression in the test sample indicates the presence of a
CC   tumour in the mammal. Mammals include dogs, cats, cattle, horses, sheep,
CC   pigs, goats and rabbits but are preferably human. The polypeptides can be
CC   used to stimulate tumour necrosis factor (TNF) alpha release from human
CC   blood, when contacted with it. A specific polypeptide can be used to
CC   stimulate the proliferation or differentiation of chondrocyte cells. The
CC   PRO proteins can be used to determine the presence of tumours and also
CC   susceptibility to tumour development, particularly adrenal, lung, colon,
CC   breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC   subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC   can be used for genetic analysis of individuals with genetic disorders.
XX
SQ   Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other;
```

```
  Query Match             85.4%;  Score 916;  DB 22;  Length 1227;
  Best Local Similarity   99.7%;  Pred. No. 0;
  Matches 1066;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       4 GCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCTCCT 63
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      12 gccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgctcct 71

Qy      64 GTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAACAT 123
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      72 gtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaacat 131

Qy     124 CCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAATGT 183
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     132 ccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaatgt 191

Qy     184 GGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCGAGA 243
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     192 ggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcgaga 251

Qy     244 CCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACAGGA 303
          |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db     252 cctgggccccaccactttaacgtgctcgccttccccctgcaaccagtttggccaacagga 311

Qy     304 GCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATTCCC 363
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     312 gcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcattccc 371

Qy     364 CATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCTGGC 423
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     372 catgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacctggc 431

Qy     424 CCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGATGG 483
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     432 ccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccagatgg 491

Qy     484 AAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGATCAC 543
          |||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||
Db     492 aaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagatcac 551

Qy     544 AGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCTCCT 603
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     552 agcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtctcct 611

Qy     604 CCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGGTGC 663
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     612 cctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatggtgc 671

Qy     664 TTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCATCAT 723
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     672 ttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccatcat 731

Qy     724 TCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAA 783
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     732 tcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaataggaa 791

Qy     784 CTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAA 843
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     792 ctcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgccaa 851

Qy     844 CAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTA 903
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     852 caaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttctgta 911

Qy     904 AACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGA 963
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     912 aactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctgtga 971

Qy     964 AAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAA 1023
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     972 aagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatataaa 1031

Qy    1024 CCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
```

```
          ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1032 ccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1080


RESULT   9
AAF44159
ID   AAF44159 standard; cDNA; 1227 BP.
XX
AC   AAF44159;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO828 (UNQ469) nucleotide sequence SEQ ID NO:188.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic;
KW   cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay; ss.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US08439.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   23-JUN-1999;   99US-0141037.
PR   07-JUL-1999;   99US-0143048.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   17-AUG-1999;   99US-0149396.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   08-OCT-1999;   99US-0158663.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2001-032160/04.
DR   P-PSDB; AAB65200.
XX
PT   PRO polynucleotides used to produce polypeptides used to target
PT   bioactive molecules such as toxins, radiolabels or antibodies, to
PT   specific cells, to cause targeted cell death -
XX
PS   Claim 2; Fig 119; 935pp; English.
XX
CC   The present invention describes human secreted and transmembrane PRO
CC   proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC   can be used for targeted delivery of bioactive molecules, such as
CC   toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC   sequences, and their fragments, can be used as hybridisation probes, in
```

```
CC   chromosomal and gene mapping, and in the generation of anti-sense RNA
CC   and DNA. They may also be used to produce transgenic animals which are
CC   used to develop and screen therapeutically useful reagents. The PRO
CC   nucleotide and protein sequence can be used for tissue typing and in
CC   treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC   AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC   in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC   AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC   sequences given in the exemplification of the present invention.
XX
SQ   Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other;


  Query Match             85.4%;  Score 916;  DB 22;  Length 1227;
  Best Local Similarity   99.7%;  Pred. No. 0;
  Matches 1066;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       4 GCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCTCCT 63
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      12 gccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgctcct 71

Qy      64 GTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAACAT 123
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      72 gtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaacat 131

Qy     124 CCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAATGT 183
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     132 ccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaatgt 191

Qy     184 GGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCGAGA 243
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     192 ggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcgaga 251

Qy     244 CCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACAGGA 303
          |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db     252 cctgggccccccaccactttaacgtgctcgccttccccctgcaaccagtttggccaacagga 311

Qy     304 GCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATTCCC 363
          |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     312 gcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcattccc 371

Qy     364 CATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCTGGC 423
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     372 catgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacctggc 431

Qy     424 CCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGATGG 483
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     432 ccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccagatgg 491

Qy     484 AAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGATCAC 543
          |||||||||||||||||||||||||||||||||||||||||||||| |||||||||
Db     492 aaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagatcac 551

Qy     544 AGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCTCCT 603
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     552 agcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtctcct 611

Qy     604 CCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGGTGC 663
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     612 cctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatggtgc 671

Qy     664 TTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCATCAT 723
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     672 ttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccatcat 731

Qy     724 TCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAA 783
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     732 tcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaataggaa 791

Qy     784 CTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAA 843
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     792 ctcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgccaa 851

Qy     844 CAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTA 903
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     852 caaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttctgta 911

Qy     904 AACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGA 963
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     912 aactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctgtga 971

Qy     964 AAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAA 1023
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     972 aagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatataaa 1031

Qy    1024 CCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          |||||||||||||||||||||||||||||||||||||||||||||||||
Db    1032 ccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1080


RESULT  10
AAF81788
ID   AAF81788 standard; cDNA; 1315 BP.
XX
AC   AAF81788;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Human secreted protein gene 2 SEQ ID NO:12.
XX
KW   Human; secreted protein; diagnosis; immunomodulatory; antisclerotic;
KW   dermatological; immunosuppressive; antiinflammatory; anti-HIV;
KW   immunostimulant; cytostatic; cardiant; vascular; anti-angiogenic;
KW   ophthalmological; neuroprotectant; nootropic; anticonvulsant; vaccine;
KW   antialzheimer; antiparkinsonian; antimicrobial; vulnerary; gene therapy;
KW   immune disorder; hyperproliferative disorder; cardiovascular disease;
KW   cancer; angiogenic disorder; neurological disorder; infectious disease;
KW   wound healing; regeneration; chemotaxis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200112775-A2.
XX
PD   22-FEB-2001.
XX
PF   16-AUG-2000; 2000WO-US22325.
XX
PR   17-AUG-1999;   99US-0149182.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ni J,  Florence KA,  Fiscella M,  Wei P,  Baker KP;
PI   Birse CE,  Young PE,  Komatsoulis GA,  Moore PA,  Soppet DR;
XX
DR   WPI; 2001-147550/15.
DR   P-PSDB; AAB74734.
XX
PT   Nucleic acids encoding 25 human secreted polypeptides, useful for
PT   preventing, diagnosing and/or treating e.g. cancers, Parkinson's
PT   disease and diabetic retinopathy -
XX
PS   Claim 1; Page 441-442; 485pp; English.
XX
CC   AAF81787 to AAF81817 encode the human secreted proteins given in AAB74733
CC   to AAB74772. Human secreted proteins can have activities based on the
CC   tissues and cells they are expressed in. Example of activities include:
CC   immunomodulatory; antisclerotic; dermatological; immunosuppressive;
CC   antiinflammatory; anti-HIV; immunostimulant; cytostatic; cardiant;
CC   vascular; anti-angiogenic; ophthalmological; neuroprotectant; nootropic;
CC   anticonvulsant; antialzheimers; antiparkinsonian; antimicrobial; and
CC   vulnerary. Human secreted proteins can be used in gene therapy and
CC   vaccine. Human secreted protein nucleotide sequences (NAM1) and proteins
CC   (PEP1) may be used in the prevention, diagnosis and treatment of diseases
CC   associated with inappropriate polypeptide expression. For example, NAM1
CC   and PEP1 may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patients genome
```

```
CC   that affect the activity of proteins by expressing inactive proteins or
CC   to supplement the patients own production of polypeptides. Disorders that
CC   may be prevented, diagnosed and/or treated include immune disorders,
CC   hyperproliferative disorders (e.g. cancers), cardiovascular diseases,
CC   angiogenic disorders, neurological disorders, infectious diseases and/or
CC   for promoting wound healing, regeneration and /or chemotaxis. AAF81778 to
CC   AAF81786 and AAB74732 represent sequences used in the exemplification of
CC   the present invention.
XX
SQ   Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 other;


  Query Match            82.3%;  Score 882;  DB 22;  Length 1315;
  Best Local Similarity  99.7%;  Pred. No. 0;
  Matches 1032;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy     38 ACGGTGGCAGCGGCGTGGCTGCTCCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGAC 97
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     47 acggtggcagcggcgtggctgctcctgtgggctgcggcctgcgcgcagcaggagcaggac 106

Qy     98 TTCTACGACTTCAAGGCGGTCAACATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGC 157
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    107 ttctacgacttcaaggcggtcaacatccggggcaaactggtgtcgctggagaagtaccgc 166

Qy    158 GGATCGGTGTCCCTGGTGGTGAATGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTAC 217
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    167 ggatcggtgtccctggtggtgaatgtggccagcgagtgcggcttcacagaccagcactac 226

Qy    218 CGAGCCCTGCAGCAGCTGCAGCGAGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTC 277
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    227 cgagccctgcagcagctgcagcgagacctgggcccccaccacttcaacgtgctcgccttc 286

Qy    278 CCCTGCAACCAGTTTGGCCAACAGGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCC 337
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    287 ccctgcaaccagtttggccaacaggagcctgacagcaacaaggagattgagagctttgcc 346

Qy    338 TGCCGCACCTACAGTGTCTCATTCCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGT 397
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    347 cgccgcacctacagtgtctcattccccatgtttagcaagattgcagtcaccggtactggt 406

Qy    398 GCCCATCCTGCCTTCAAGTACCTGGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTC 457
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    407 gcccatcctgccttcaagtacctggcccagacttctgggaaggagcccacctggaacttc 466

Qy    458 TGGAAGTACCTAGTAGCCCCAGATGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCA 517
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    467 tggaagtacctagtagccccagatggaaaggtggtaggggcttgggacccaactgtgtca 526

Qy    518 GTGGAGGAGGTCAGACTCCAGATCACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGA 577
        |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db    527 gtggaggaggtcagaccccagatcacagcgctcgtgaggaagctcatcctactgaagcga 586

Qy    578 GAAGACTTATAACCACCGCGTCTCCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGG 637
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    587 gaagacttataaccaccgcgtctcctcctccaccacctcatcccgcccacctgtgtgggg 646

Qy    638 CTGACCAATGCAAACTCAAATGGTGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTT 697
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    647 ctgaccaatgcaaactcaaatggtgcttcaaagggagagacccactgactctccttcctt 706

Qy    698 TACTCTTATGCCATTGGTCCCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTAT 757
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    707 tactcttatgccattggtcccatcattcttgtgggggaaaaattctagtattttgattat 766

Qy    758 TTGAATCTTACAGCAACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATC 817
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    767 ttgaatcttacagcaacaaataggaactcctggccaatgagagctcttgaccagtgaatc 826

Qy    818 ACCAGCCGATACGAACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCA 877
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    827 accagccgatacgaacgtcttgccaacaaaaatgtgtggcaaatagaagtatatcaagca 886

Qy    878 ATAATCTCCCACCCAAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTG 937
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    887 ataatctcccacccaaggcttctgtaaactgggaccaatgattacctcatagggctgttg 946

Qy    938 TGAGGATTAGGATGAAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCA 997
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    947 tgaggattaggatgaaatacctgtgaaagtgcctaggcagtgccagccaaataggaggca 1006

Qy    998 TTCAATGAACATTTTTTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCA 1057
        |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db   1007 ttcaatgaacatttttgcacataaaccaaaaaataacttgttatcaataaaaacttgca 1066

Qy   1058 TCCAACATGAATTTC 1072
        ||||||||||||||||
Db   1067 tccaacatgaatttc 1081


RESULT  11
AAH06810
ID   AAH06810 standard; cDNA; 872 BP.
XX
AC   AAH06810;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human cDNA clone (5'-primer) SEQ ID NO:3645.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 1; SEQ ID 3645; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
```

```
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 872 BP; 197 A; 259 C; 233 G; 183 T; 0 other;


  Query Match           59.0%;  Score 632;  DB 22;  Length 872;
  Best Local Similarity  99.6%;  Pred. No. 5.4e-305;
  Matches  782;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      15 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 74

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      75 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 134

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     135 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 194

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     195 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 254

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Db     255 agacctgggccccaccactttaacgtgctcgccttccctgcaaccagtttggccaaca 314

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Db     315 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 374

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     375 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 434

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     435 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 494

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     495 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 554

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     555 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 614

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     615 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 674

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     675 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 734

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     735 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 794

Qy     781 GAACT 785
          |||||
Db     795 gaact 799


RESULT  12
AAH71016/c
ID   AAH71016 standard; cDNA; 751 BP.
XX
AC   AAH71016;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 2290.
XX
KW   Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681.
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600.
PR   21-JUL-2000; 2000US-0220114.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Deeds J,  Berger A,  Zhao X;
XX
DR   WPI; 2001-375006/39.
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 484; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 751 BP; 194 A; 141 C; 143 G; 269 T; 4 other;


  Query Match           33.7%;  Score 361;  DB 22;  Length 751;
  Best Local Similarity  100.0%;  Pred. No. 8.1e-170;
  Matches  361;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     712 TGGTCCCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGC 771
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     684 TGGTCCCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGC 625

Qy     772 AACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGA 831
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     624 AACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGA 565

Qy     832 ACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCC 891
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     564 ACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCC 505

Qy     892 AAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATG 951
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     504 AAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATG 445

Qy     952 AAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTT 1011
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     444 AAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTT 385

Qy    1012 TTTGCATATAAACCAAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTT 1071
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db    384 TTTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTT 325

Qy   1072 C 1072
          |
Db    324 C 324


RESULT  13
AAH72087/c
ID   AAH72087 standard; cDNA; 468 BP.
XX
AC   AAH72087;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 3361.
XX
KW   Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681.
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600.
PR   21-JUL-2000; 2000US-0220114.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Deeds J,  Berger A,  Zhao X;
XX
DR   WPI; 2001-375006/39.
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 652; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 468 BP; 131 A; 84 C; 94 G; 159 T; 0 other;


  Query Match             33.2%;  Score 356;  DB 22;  Length 468;
  Best Local Similarity   100.0%;  Pred. No. 2.5e-167;
  Matches  356;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    717 CCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAA 776
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    468 CCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAA 409

Qy    777 ATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTC 836
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    408 ATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTC 349

Qy    837 TTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGC 896
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    348 TTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGC 289

Qy    897 TTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATA 956
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    288 TTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATA 229

Qy    957 CCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGC 1016
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    228 CCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGC 169

Qy   1017 ATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    168 ATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 113


RESULT  14
AAH11842/c
ID   AAH11842 standard; cDNA; 528 BP.
XX
AC   AAH11842;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human cDNA clone (3'-primer) SEQ ID NO:8677.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 3; SEQ ID 8677; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
```

```
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 528 BP; 153 A; 89 C; 108 G; 177 T; 1 other;


  Query Match            32.0%;  Score 343;  DB 22;  Length 528;
  Best Local Similarity  100.0%;  Pred. No. 7.8e-161;
  Matches  343;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     730 GGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAACTCCTG 789
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     485 GGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAACTCCTG 426

Qy     790 GCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAACAAAAA 849
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     425 GCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAACAAAAA 366

Qy     850 TGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTAAACTGG 909
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     365 TGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTAAACTGG 306

Qy     910 GACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGAAAGTGC 969
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     305 GACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGAAAGTGC 246

Qy     970 CTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAACCAAAA 1029
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     245 CTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAACCAAAA 186

Qy    1030 AATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           |||||||||||||||||||||||||||||||||||||||||||
Db     185 AATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 143


RESULT  15
AAZ65182
ID   AAZ65182 standard; DNA; 50 BP.
XX
AC   AAZ65182;
XX
DT   05-APR-2000  (first entry)
XX
DE   Probe specific for human PRO828.
XX
KW   Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW   pharmaceutical; receptor immunoadhesin; gene mapping; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO9963088-A2.
XX
PD   09-DEC-1999.
XX
PF   02-JUN-1999;   99WO-US12252.
XX
PR   02-JUN-1998;   98US-0087607.
PR   02-JUN-1998;   98US-0087609.
PR   02-JUN-1998;   98US-0087759.
PR   03-JUN-1998;   98US-0087827.
PR   04-JUN-1998;   98US-0088021.
PR   04-JUN-1998;   98US-0088025.
PR   04-JUN-1998;   98US-0088028.
PR   04-JUN-1998;   98US-0088029.
PR   04-JUN-1998;   98US-0088030.
PR   04-JUN-1998;   98US-0088033.
PR   04-JUN-1998;   98US-0088326.
PR   05-JUN-1998;   98US-0088167.
PR   05-JUN-1998;   98US-0088202.
PR   05-JUN-1998;   98US-0088212.
PR   05-JUN-1998;   98US-0088217.
PR   09-JUN-1998;   98US-0088655.
PR   10-JUN-1998;   98US-0088722.
PR   10-JUN-1998;   98US-0088730.
PR   10-JUN-1998;   98US-0088734.
PR   10-JUN-1998;   98US-0088738.
PR   10-JUN-1998;   98US-0088740.
PR   10-JUN-1998;   98US-0088741.
PR   10-JUN-1998;   98US-0088742.
PR   10-JUN-1998;   98US-0088810.
PR   10-JUN-1998;   98US-0088811.
PR   10-JUN-1998;   98US-0088824.
PR   10-JUN-1998;   98US-0088825.
PR   10-JUN-1998;   98US-0088826.
PR   11-JUN-1998;   98US-0088858.
PR   11-JUN-1998;   98US-0088861.
PR   11-JUN-1998;   98US-0088863.
PR   11-JUN-1998;   98US-0088876.
PR   12-JUN-1998;   98US-0089090.
PR   12-JUN-1998;   98US-0089105.
PR   16-JUN-1998;   98US-0089440.
PR   16-JUN-1998;   98US-0089512.
PR   16-JUN-1998;   98US-0089514.
PR   17-JUN-1998;   98US-0089532.
PR   17-JUN-1998;   98US-0089538.
PR   17-JUN-1998;   98US-0089598.
PR   17-JUN-1998;   98US-0089599.
PR   17-JUN-1998;   98US-0089600.
PR   17-JUN-1998;   98US-0089653.
PR   18-JUN-1998;   98US-0089801.
PR   18-JUN-1998;   98US-0089907.
PR   18-JUN-1998;   98US-0089908.
PR   19-JUN-1998;   98US-0089947.
PR   19-JUN-1998;   98US-0089948.
PR   19-JUN-1998;   98US-0089952.
PR   22-JUN-1998;   98US-0090246.
PR   22-JUN-1998;   98US-0090252.
PR   22-JUN-1998;   98US-0090254.
PR   23-JUN-1998;   98US-0090349.
PR   23-JUN-1998;   98US-0090355.
PR   24-JUN-1998;   98US-0090429.
PR   24-JUN-1998;   98US-0090431.
PR   24-JUN-1998;   98US-0090435.
PR   24-JUN-1998;   98US-0090444.
PR   24-JUN-1998;   98US-0090445.
PR   24-JUN-1998;   98US-0090461.
PR   24-JUN-1998;   98US-0090472.
PR   24-JUN-1998;   98US-0090535.
PR   24-JUN-1998;   98US-0090538.
PR   24-JUN-1998;   98US-0090540.
PR   24-JUN-1998;   98US-0090557.
PR   25-JUN-1998;   98US-0090676.
PR   25-JUN-1998;   98US-0090678.
PR   25-JUN-1998;   98US-0090688.
PR   25-JUN-1998;   98US-0090690.
PR   25-JUN-1998;   98US-0090691.
PR   25-JUN-1998;   98US-0090694.
PR   25-JUN-1998;   98US-0090695.
PR   25-JUN-1998;   98US-0090696.
PR   26-JUN-1998;   98US-0090862.
PR   26-JUN-1998;   98US-0090863.
PR   01-JUL-1998;   98US-0091358.
PR   01-JUL-1998;   98US-0091360.
PR   01-JUL-1998;   98US-0091544.
PR   02-JUL-1998;   98US-0091478.
PR   02-JUL-1998;   98US-0091486.
PR   02-JUL-1998;   98US-0091519.
PR   02-JUL-1998;   98US-0091626.
PR   02-JUL-1998;   98US-0091628.
PR   02-JUL-1998;   98US-0091633.
PR   02-JUL-1998;   98US-0091646.
PR   02-JUL-1998;   98US-0091673.
PR   07-JUL-1998;   98US-0091978.
PR   07-JUL-1998;   98US-0091982.
PR   09-JUL-1998;   98US-0092182.
PR   10-JUL-1998;   98US-0092472.
```

PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.
PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
DR WPI; 2000-072883/06.
XX
PT Membrane-bound proteins and related nucleotide sequences -
XX
PS Example 50; Page 418; 822pp; English.
XX
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX

SQ Sequence 50 BP; 11 A; 12 C; 18 G; 9 T; 0 other;

Query Match 4.7%; Score 50; DB 21; Length 50;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 118 CAACATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGT 167
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 caacatccggggcaaactggtgtcgctggagaagtaccgcggatcggtgt 50

Search completed: August 25, 2002, 07:18:34
Job time: 3889 sec